Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Akari Therapeutics ( (AKTX) ) has shared an update.
Akari Therapeutics announced a significant amendment to its convertible promissory notes and warrants, initially issued by Peak Bio, following their merger in November 2024. The changes include extending maturity and expiration dates and adjusting conversion and exercise prices, which could impact the company’s financial strategy and stakeholder interests. Additionally, on September 24, 2025, Akari revealed promising preclinical data for its novel ADC payload, PH1, showing potential in treating prostate cancer driven by AR-V7, a variant linked to resistance against current therapies. This development may lead to new combination regimens with existing drugs, potentially enhancing treatment efficacy and slowing resistance development.
The most recent analyst rating on (AKTX) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Akari Therapeutics stock, see the AKTX Stock Forecast page.
Spark’s Take on AKTX Stock
According to Spark, TipRanks’ AI Analyst, AKTX is a Neutral.
Akari Therapeutics’ stock score of 44 reflects significant challenges due to its current financial instability and lack of revenue. While the technical analysis indicates a neutral trend, the company’s speculative nature due to the absence of traditional valuation metrics underscores the risk. However, the recent positive corporate event with the appointment of a new CEO brings some potential for strategic improvement, slightly offsetting the otherwise high-risk profile.
To see Spark’s full report on AKTX stock, click here.
More about Akari Therapeutics
Akari Therapeutics operates in the biopharmaceutical industry, focusing on developing treatments for cancer and other diseases. The company is involved in creating novel antibody drug conjugates (ADCs) and has a market focus on addressing tumors driven by alternative splicing-drivers.
Average Trading Volume: 166,397
Technical Sentiment Signal: Sell
Current Market Cap: $36.2M
For a thorough assessment of AKTX stock, go to TipRanks’ Stock Analysis page.